AI Cancer Vaccine Achieves 75% Melanoma Response and 3-Year Remission: Evaxion Data at SITC 2026

AI-generated summary Evaxion A/S presented data at the Society for Immunotherapy of Cancer showing a 75% objective response rate for its personalized peptide cancer vaccine EVX-01 combined with Merck's pembrolizumab in advanced melanoma patients. Senior Scientist Mads Lausen of Evaxion presented systemic immunomodulatory findings examining how EVX-01 reshapes the immune system to support ongoing durability.

Gartner forecasts a net gain of 1.7 million AI-related jobs by 2030

11 November 2026

www.aiaffairs.com — The forecast puts the public sector on the losing side of the jobs balance, while Gartner expects far more workers to see…

Authentic Brands Group built AuthOS AI system with 50 agents on Google Cloud

11 November 2026

aipractice.osuslova.pro — Authentic Brands Group built AuthOS on Gemini Enterprise Agent Platform. AI-enhanced Reebok images delivered 60% higher ROAS.

Claude Sheets, Whiteboards and Data

10 November 2026

artificiallynerdy.com — Claude Sheets and Whiteboards launched in beta Nov 10, 2026, and Claude Data is now generally available on all paid plans. What each does and how to start.

10 November 2026: Daily AI News Updates

10 November 2026

aiuniversejournal.org — Daily AI News Updates for 10 November 2026: Randomized Trial Protocol: Head-to-Head Comparison of Two Ambient Artificial Intelligence Documentation Tools on…

Salesforce Cresta Acquisition: What Buyers Face

9 November 2026

www.cognativ.com — Salesforce is buying Cresta, whose voice agents run on Five9, Genesys, NICE and HubSpot. What the deal means if you buy contact-center AI elsewhere.